Oral Hypoglycemic Agents Global Market Report 2025
상품코드:1760661
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
경구 혈당강하제 시장 규모는 향후 몇 년 동안 강력한 성장을 보일 것으로 예상됩니다. 예측 기간 동안, 복합 요법에 대한 수요 증가, 정부의 의료 지원 정책, 당뇨병 치료를 위한 원격 의료의 채택 증가, 당뇨병 치료 연구 및 개발에 대한 투자 증가, 개인 맞춤형 치료에 대한 관심 증가 등이 성장을 촉진할 것으로 예상됩니다. 이 기간의 주요 동향으로는 새로운 경구용 항당뇨병 의약품의 개발, 고정 용량 복합제의 개발, 의약품 제형 기술의 발전, 의약품 부작용 감소 노력, 포도당 모니터링을 위한 디지털 건강 도구의 통합 등이 있습니다.
제 2형 당뇨병의 유병률 증가는 경구 혈당강하제 시장의 성장을 촉진할 것으로 예상됩니다. 제 2형 당뇨병은 신체가 인슐린을 효과적으로 사용하지 못해 혈당 수치가 높아지는 만성 대사 장애입니다. 제 2형 당뇨병의 증가는 주로 신체 활동을 감소시키고 비만 및 인슐린 저항성을 유발하는 앉아있는 생활 방식의 증가에 기인합니다. 경구 혈당강하제는 인슐린 민감도 개선, 인슐린 분비 촉진, 또는 포도당 흡수 감소 등을 통해 혈당을 낮추어 제2형 당뇨병을 관리하는 데 사용됩니다. 국제 당뇨병 연맹(IDF)에 따르면, 2025년 4월 기준으로 20-79세 성인 중 5억 8,900만명이 당뇨병을 앓고 있으며, 이 수는 2050년까지 8억 5,300만명으로 증가할 것으로 예측되고 있습니다.
경구 혈당강하제 시장의 주요 기업들은 제 2형 당뇨병 환자의 혈당 조절을 개선하기 위해 디펩티딜 펩티다제-4(DPP-4) 억제제를 비롯한 첨단 치료제 개발에 주력하고 있습니다. DPP-4 억제제는 인크레틴 호르몬 수치를 증가시켜 인슐린 생성을 촉진하여 혈당 수치를 낮추는 약물입니다. 예를 들어, 2022년 6월, 중국에 본사를 둔 제약 회사인 Gan & Lee Pharmaceuticals Co. Ltd.는 제 2형 당뇨병을 효과적으로 관리하기 위해 개발된 경구 혈당강하제인 Sitagliptin Phosphate 정제의 승인을 받았습니다. 이 제품은 DPP-4 효소를 억제하여 혈당 수치를 조절하는 작용을 하며, Gan & Lee Pharmaceuticals가 제네릭 의약품 시장에 진출하여 제 2형 당뇨병을 관리하기 위한 보다 저렴한 옵션을 제공하게 되었습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 경구 혈당강하제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 경구 혈당강하제 시장 : 성장률 분석
세계의 경구 혈당강하제 시장 실적 : 규모와 성장(2019-2024년)
세계의 경구 혈당강하제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 경구 혈당강하제 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 경구 혈당강하제 시장 : 제품 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
설포닐우레아제
메트포르민
티아졸리딘디온
α-글루코시다아제 억제제
면역요법
세계의 경구 혈당강하제 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구정
경구액
서방형 제제
병용 요법 제제
세계의 경구 혈당강하제 시장 : 환자 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제 2형 당뇨병 환자
당뇨병 전증 환자
비만 또는 과체중 환자
여러 합병증을 가진 환자
세계의 경구 혈당강하제 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
장기 케어 시설
세계의 경구 혈당강하제 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
클리닉
세계의 경구 혈당강하제 시장 : 설포닐우레아제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
글리피지드
글리브리드
그리메피리드
클로르프로파미드
톨부타미드
세계의 경구 혈당강하제 시장 : 메트포르민 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
즉방성 메트포르민
서방형 메트포르민(XR)
메트포르민 병용
세계의 경구 혈당강하제 시장 : 티아졸리딘디온(TZD) 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
피오글리타존
로시글리타존
세계의 경구 혈당강하제 시장 : α-글루코시다아제 억제제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
아카르보스
미글리톨
보그리보스
세계의 경구 혈당강하제 시장 : 면역요법 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
테프리주맙
명반 배합 GAD(GAD-명반)
디아미드
항CD3 단일클론항체
제7장 지역별, 국가별 분석
세계의 경구 혈당강하제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 경구 혈당강하제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
경구 혈당강하제 시장 :경쟁 구도
경구 혈당강하제 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Janssen Global Services LLC : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck Sharp & Dohme Corp. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Sanofi SA
AstraZeneca plc
Novartis AG
GSK plc
Takeda Pharmaceuticals Limited
Eli Lilly and Company
Boehringer Ingelheim Ltd.
Novo Nordisk A/S
Astellas Pharma Inc.
Laboratoires Servier
Huadong Medicine Co. Ltd.
Tonghua Dongbao Pharmaceutical Co. Ltd.
Gan & Lee Pharmaceuticals Co. Ltd.
Biocon Limited
Wanbang Biopharmaceuticals Co. Ltd.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
경구 혈당강하제 시장(2029년) : 새로운 기회를 제공하는 국가
경구 혈당강하제 시장(2029년) : 새로운 기회를 제공하는 부문
경구 혈당강하제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Oral hypoglycemic agents (OHAs) are medications taken orally to help reduce blood glucose (sugar) levels in individuals with type 2 diabetes mellitus. These medications work through different mechanisms, including increasing insulin secretion, enhancing insulin sensitivity, decreasing glucose absorption from the gut, or reducing glucose production by the liver. OHAs are typically prescribed when lifestyle changes, such as diet and exercise, are not enough to control blood sugar levels.
The primary types of oral hypoglycemic agents include sulfonylureas, metformin, thiazolidinediones, alpha-glucosidase inhibitors, and immunotherapy. Sulfonylureas are a class of oral hypoglycemic agents that stimulate the pancreas to release more insulin by targeting beta cells, which helps lower blood glucose levels in individuals with type 2 diabetes. These drugs are available in various forms, such as oral tablets, oral liquids, extended-release formulations, and combination therapy formulations. The patient groups include individuals with type 2 diabetes mellitus, pre-diabetic patients, obese or overweight individuals, and those with multiple comorbidities. They are distributed through various channels like hospital pharmacies, retail pharmacies, online pharmacies, and nursing homes or long-term care facilities. The main end users are hospitals and clinics.
The oral hypoglycemic agents market research report is one of a series of new reports from The Business Research Company that provides oral hypoglycemic agents market statistics, including the oral hypoglycemic agents industry global market size, regional shares, competitors with the oral hypoglycemic agents market share, detailed oral hypoglycemic agents market segments, market trends, and opportunities, and any further data you may need to thrive in the oral hypoglycemic agents industry. This oral hypoglycemic agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The oral hypoglycemic agents market size has grown strongly in recent years. It will grow from $57.04 billion in 2024 to $60.15 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth during the historic period can be attributed to factors such as the increasing prevalence of type 2 diabetes, a rising geriatric population, greater awareness of diabetes management, expanded healthcare access in emerging markets, and a preference for oral therapies over injectable ones.
The oral hypoglycemic agents market size is expected to see strong growth in the next few years. It will grow to $73.69 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. In the forecast period, growth is expected to be driven by a rising demand for combination therapies, supportive government healthcare policies, increased adoption of telemedicine for diabetes care, greater investment in research and development for diabetes treatments, and a stronger focus on personalized treatment approaches. Key trends in this period include the development of novel oral antidiabetic drugs, the creation of fixed-dose combinations, advancements in drug formulation technologies, efforts to reduce drug side effects, and the integration of digital health tools for glucose monitoring.
The increasing prevalence of type 2 diabetes is expected to drive the growth of the oral hypoglycemic agents market. Type 2 diabetes is a chronic metabolic disorder where the body becomes ineffective in using insulin, resulting in high blood glucose levels. The rise in type 2 diabetes is largely due to more sedentary lifestyles, which reduce physical activity and contribute to obesity and insulin resistance. Oral hypoglycemic agents are used to manage type 2 diabetes by lowering blood glucose through mechanisms such as improving insulin sensitivity, stimulating insulin production, or reducing glucose absorption. According to the International Diabetes Federation (IDF), nearly 589 million adults aged 20-79 are living with diabetes worldwide as of April 2025, and this number is projected to rise to 853 million by 2050. This increasing incidence of type 2 diabetes is expected to drive market growth for oral hypoglycemic agents.
Leading companies in the oral hypoglycemic agents market are concentrating on developing advanced therapeutic options, including dipeptidyl peptidase-4 (DPP-4) inhibitors, to enhance blood sugar control for type 2 diabetes patients. DPP-4 inhibitors are medications that increase incretin hormone levels, stimulating insulin production to reduce blood sugar levels. For example, in June 2022, Gan & Lee Pharmaceuticals Co. Ltd., a China-based pharmaceutical company, received approval for Sitagliptin Phosphate tablets, an oral hypoglycemic medication designed to manage type 2 diabetes effectively. This product works by inhibiting the DPP-4 enzyme, helping regulate blood sugar levels, and marks Gan & Lee Pharmaceuticals' entry into the generic drug market, offering a more affordable option for managing type 2 diabetes.
In July 2024, F. Hoffmann-La Roche Ltd., a Swiss pharmaceutical company, acquired Carmot Therapeutics Inc. for $2.7 billion. This acquisition allows Roche to strengthen its position in the obesity and diabetes treatment market by expanding its portfolio of incretin-based therapies. Carmot Therapeutics Inc., based in the US, specializes in developing incretin-based treatments for obesity, diabetes, and related metabolic conditions.
Major players in the oral hypoglycemic agents market are Pfizer Inc., Janssen Global Services LLC, Merck Sharp & Dohme Corp., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceuticals Limited, Eli Lilly and Company, Boehringer Ingelheim Ltd., Novo Nordisk A/S, Astellas Pharma Inc., Laboratoires Servier, Huadong Medicine Co. Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Gan & Lee Pharmaceuticals Co. Ltd., Biocon Limited, Wanbang Biopharmaceuticals Co. Ltd.
North America was the largest region in the oral hypoglycemic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oral hypoglycemic agents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the oral hypoglycemic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The oral hypoglycemic agents market consists of sales of DPP-4 inhibitors, alpha-glucosidase inhibitors, biguanides, and thiazolidinediones (TZDs). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Oral Hypoglycemic Agents Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on oral hypoglycemic agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for oral hypoglycemic agents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oral hypoglycemic agents market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
3. Oral Hypoglycemic Agents Market Trends And Strategies
4. Oral Hypoglycemic Agents Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Oral Hypoglycemic Agents Growth Analysis And Strategic Analysis Framework
5.1. Global Oral Hypoglycemic Agents PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Oral Hypoglycemic Agents Market Growth Rate Analysis
5.4. Global Oral Hypoglycemic Agents Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Oral Hypoglycemic Agents Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Oral Hypoglycemic Agents Total Addressable Market (TAM)
6. Oral Hypoglycemic Agents Market Segmentation
6.1. Global Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sulfonylureas
Metformin
Thiazolidinediones
Alpha-Glucosidase Inhibitors
Immunotherapy
6.2. Global Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Tablets
Oral Liquids
Extended-Release Formulations
Combination Therapy Formulations
6.3. Global Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Type 2 Diabetes Mellitus Patients
Pre-Diabetic Patients
Obese Or Overweight Patients
Patients With Multiple Comorbidities
6.4. Global Oral Hypoglycemic Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Nursing Homes and Long-Term Care Facilities
6.5. Global Oral Hypoglycemic Agents Market, Segmentation By End users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
6.6. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Sulfonylureas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Glipizide
Glyburide
Glimepiride
Chlorpropamide
Tolbutamide
6.7. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Metformin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immediate-Release Metformin
Extended-Release Metformin (XR)
Combination Metformin
6.8. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Thiazolidinediones (TZDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pioglitazone
Rosiglitazone
6.9. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Alpha-Glucosidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acarbose
Miglitol
Voglibose
6.10. Global Oral Hypoglycemic Agents Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Teplizumab
Alum-Formulated GAD (GAD-Alum)
Diamyd
Anti-CD3 Monoclonal Antibodies
7. Oral Hypoglycemic Agents Market Regional And Country Analysis
7.1. Global Oral Hypoglycemic Agents Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Oral Hypoglycemic Agents Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Oral Hypoglycemic Agents Market
9.1. China Oral Hypoglycemic Agents Market Overview
9.2. China Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Oral Hypoglycemic Agents Market
10.1. India Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Oral Hypoglycemic Agents Market
11.1. Japan Oral Hypoglycemic Agents Market Overview
11.2. Japan Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Oral Hypoglycemic Agents Market
12.1. Australia Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Oral Hypoglycemic Agents Market
13.1. Indonesia Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Oral Hypoglycemic Agents Market
14.1. South Korea Oral Hypoglycemic Agents Market Overview
14.2. South Korea Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Oral Hypoglycemic Agents Market
15.1. Western Europe Oral Hypoglycemic Agents Market Overview
15.2. Western Europe Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Oral Hypoglycemic Agents Market
16.1. UK Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Oral Hypoglycemic Agents Market
17.1. Germany Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Oral Hypoglycemic Agents Market
18.1. France Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Oral Hypoglycemic Agents Market
19.1. Italy Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Oral Hypoglycemic Agents Market
20.1. Spain Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Oral Hypoglycemic Agents Market
21.1. Eastern Europe Oral Hypoglycemic Agents Market Overview
21.2. Eastern Europe Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Oral Hypoglycemic Agents Market
22.1. Russia Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Oral Hypoglycemic Agents Market
23.1. North America Oral Hypoglycemic Agents Market Overview
23.2. North America Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Oral Hypoglycemic Agents Market
24.1. USA Oral Hypoglycemic Agents Market Overview
24.2. USA Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Oral Hypoglycemic Agents Market
26.1. South America Oral Hypoglycemic Agents Market Overview
26.2. South America Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Oral Hypoglycemic Agents Market
27.1. Brazil Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Oral Hypoglycemic Agents Market
28.1. Middle East Oral Hypoglycemic Agents Market Overview
28.2. Middle East Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Oral Hypoglycemic Agents Market
29.1. Africa Oral Hypoglycemic Agents Market Overview
29.2. Africa Oral Hypoglycemic Agents Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Oral Hypoglycemic Agents Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Oral Hypoglycemic Agents Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Oral Hypoglycemic Agents Market Competitive Landscape And Company Profiles
